Study On Relation Between Tissue Factor Pathway Inhibitor And Blood Compatibility Of Biomaterials

At present, it is an effective way to use artificial organs and medical devices made of biomaterials to cure organ abnormalities. Each year the lives of millions patients are saved with artificial heart valves and liver as well as artificial kidney and left heart assistant device. And innumerable artificial organs are used to rehabilitate people's organ defect. In recent years , the study on tissue engineering is springing up and developing flourishingly, it brings with the new vigor to the research of artificial organs and medical devices, and increases the developing speed of manufacturing of artificial organs and medical devices. It is expected that ninety percent of human organs except cerebra can be substituted and rehabbed with artificial organs. We can expect that investigation and invention of new artificial organs and medical devices will become the important power to impel the development of medical sciences and techniques. And it will be possibly to be one of the important support industry in the coming century. Nevertheless, the problem of thrombosis caused by artificial organs and medical devices still remains by now. It not only severely intimidates the lives and health of patients, but also restricts their clinical application in therapy of human diseases. To prevent the formation of thrombus induced by artificial organs and medical devices and increase the blood compatibility of biomaterials are the urgent work for us to do in the research field of biomedical engineering now.For a long time, many scientists have been making great efforts in order to increase the haemocompatibility of biomaterials, and have already made a great progress. But all previous studies are limited to the interaction between biomaterials and intrinsic coagulation factors as well as platelets. Usually people adopt the methods of blocking the formation of thrombin and activation of platelet to avoid the thrombus formation induced by biomaterials, but the role of TF in blood coagulation hadn't been studied before 1990's. This may be the reason why the thrombosis problem couldn't be solved until now. Heretofore, a large number of studies have proved that TF plays a dominant role in the thrombus formation caused by biomaterials. Tissue factor pathway inhibitor is a natural inhibitor of TF in blood of mammal. It is also the research hotspot in the field of hematology in the world. It is very important to study the relation between TFPI and biomaterial haemocompatibility. But it is a problem to get enough amount of TFPI to do related research work. Since the concentration of TFPI is low in blood(100ng/ml).In this paper, our objective is to produce recombinant TFPI from E. Coli., to investigate the relation between rTFPI and biomaterial hemocompatibility , to explore the mechanism of effect of rTFPI on biomaterial hemocompatibility, and to examine the usefulness of rTFPI in implantation of biomaterials.Methods: (1) Expression and purification of rTFPI: Human TFPI cDNA was inserted into pGEX-2T vector and the ligate was transfected into E. Coli. BL-21 cells. The positive...